Research that has transformed scientists’ understanding of the brain and neurodegenerative diseases like Alzheimer’s has been awarded the 2014 Newcomb Cleveland Prize of the American Association for the Advancement of Science (AAAS).
The Association’s oldest honor, the prize annually recognizes the author or authors of an outstanding paper published in the journal Science, and will be awarded this year for a study that appeared in the October 2013 edition of journal, entitled “Sleep Drives Metabolite Clearance from the Adult Brain.” The prize will be presented on Friday, February 13, at the AAAS Annual Meeting in San Jose, California.
Amy Or, Wall Street Journal, 17 December 2014
Norwest Venture Partners’ portfolio company iCardiac Technologies Inc. may have a way to help pharmaceutical companies detect which experimental drugs might flat line over cardiac concerns.
The Rochester, N.Y.-based company recently completed a study in collaboration with the U.S. Food and Drug Administration which demonstrated that cardiac toxicity in drugs can be detected much earlier in the development process than previously thought by medical professionals.
Read the complete article here.
Chunlei Guo, professor of optics, is scheduled to be a guest on Science Friday today at 2 p.m. Guo is set to talk about his research on using lasers to create superhydrophobic metals. The show airs on NPR. Tune in locally to WXXI AM1370.
The National Science Foundation today announced that the University of Rochester has been selected for an I-Corps site Award. This 3-year, $300,000 award will give Rochester the resources necessary to support further development of as many as 30 projects per year. Funds may be used to explore markets, conduct customer discovery inquiries, develop prototypes, or otherwise transition scientific discoveries into viable products and services. Any discovery made through NSF funding is eligible for consideration.
Dr. Goldman’s human glial mouse model has been written up in New Scientist.
The idea is not to mimic fiction, but to advance our understanding of human brain diseases by studying them in whole mouse brains rather than in dishes.
The altered mice still have mouse neurons – the “thinking” cells that make up around half of all their brain cells. But practically all the glial cells in their brains, the ones that support the neurons, are human.
“It’s still a mouse brain, not a human brain,” says Steve Goldman of the University of Rochester Medical Center in New York. “But all the non-neuronal cells are human.”
Read the entire article
Four prominent Rochester researchers shared the state of their research and their experiences discovering and developing useful drugs. Mark Noble, Ph.D., (Biomedical Genetics), Paul Dunman, Ph.D. (Microbiology & Immunology), Harold Smith, Ph.D. (Biochemistry & Biophysics), and Richard Phipps, Ph.D. (Environmental Medicine) all spoke about some of the interesting projects they are working on and some of the struggles and successes they have encountered along the way.
Omar Bakht of UR Ventures opening the 2014 Rochester Drug Discovery Symposium.
2014 Rochester Drug Discovery Symposium
High Tech Rochester’s Lennox Tech Enterprise Center, by virtue of its association with the University of Rochester, is a tax-free zone under the new START-UP NY economic development program.
Taking advantage of HTR’s designation, PharmAdva LLC (www.pharmadva.com), a startup healthcare technology company with roots at the University of Rochester, will locate at HTR. PharmAdva produces and markets an in-home medication-adherence system designed to help people manage multiple medications at home and avoid unnecessary hospitalization or nursing home admission.
The University of Rochester has been identified by the journal Nature Biotechnology as one of the top 10 universities in the nation for the impact of its life sciences research.
“This recognition reflects not only the University’s success in attracting federal research funding, but our ability to translate this research into new ideas and technologies that stimulate economic activity and will ultimately improve lives,” said Stephen Dewhurst, Ph.D., vice dean for Research at the University of Rochester School of Medicine and Dentistry. “It is a testament to the exceptional quality of our scientists and more evidence that our faculty continue to outperform their peers when it comes to the impact of our scientific innovation.”
They started with 6,932 applications from 96 countries and all 50 states. On 30 October 2014, the 11 finalists pitched their business plans to the judges.
And the results are . . .
PharmAdva LLC, a medical device manufacturer, has been approved to participate in the START-UP NY economic development program. The company will locate in High Tech Rochester’s (HTR) Lennox Tech Enterprise Center in Henrietta.